Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2017 Summary Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 4 and 1 respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Respiratory and Musculoskeletal Disorders which include indications Actinic (Solar) Keratosis, Cutaneous T-Cell Lymphoma, Solid Tumor, Systemic Lupus Erythematosus, Allergic Rhinitis, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Inflammatory Bowel Disease, Melanoma, Pancreatic Cancer, Perennial Allergic Rhinitis, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Seasonal Allergic Rhinitis, Sicca Syndrome (Sjogren), Ulcerative Colitis and Warts. The latest report Toll Like Receptor 8 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8) - The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects - The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Toll Like Receptor 8 (CD288 or TLR8) - Overview Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development Dynavax Technologies Corp Galderma SA Gilead Sciences Inc Idera Pharmaceuticals Inc Janus Biotherapeutics Inc MedImmune LLC VentiRx Pharmaceuticals Inc Vivelix Pharmaceuticals Ltd Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles 854-A - Drug Profile Product Description Mechanism Of Action R&D Progress DV-1001 - Drug Profile Product Description Mechanism Of Action R&D Progress GS-9688 - Drug Profile Product Description Mechanism Of Action R&D Progress IMO-8400 - Drug Profile Product Description Mechanism Of Action R&D Progress IMO-9200 - Drug Profile Product Description Mechanism Of Action R&D Progress JB-6121 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-9197 - Drug Profile Product Description Mechanism Of Action R&D Progress motolimod - Drug Profile Product Description Mechanism Of Action R&D Progress resiquimod - Drug Profile Product Description Mechanism Of Action R&D Progress RSLV-132 - Drug Profile Product Description Mechanism Of Action R&D Progress VTX-1463 - Drug Profile Product Description Mechanism Of Action R&D Progress VTX-294 - Drug Profile Product Description Mechanism Of Action R&D Progress VTX-763 - Drug Profile Product Description Mechanism Of Action R&D Progress Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones Featured News & Press Releases Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom's Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Dynavax Technologies Corp, H1 2017 Pipeline by Galderma SA, H1 2017 Pipeline by Gilead Sciences Inc, H1 2017 Pipeline by Idera Pharmaceuticals Inc, H1 2017 Pipeline by Janus Biotherapeutics Inc, H1 2017 Pipeline by MedImmune LLC, H1 2017 Pipeline by VentiRx Pharmaceuticals Inc, H1 2017 Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
